TARA-002 Shows Durable 12-Month Complete Response in NMIBC Phase 2 Trial with Strong Safety Profile
Durable Efficacy Data Underscore TARA-002’s Potential for BCG-Naïve NMIBC Patients
Protara Therapeutics has announced compelling new results from its ongoing Phase 2 ADVANCED-2 trial, testing the investigational cell therapy TARA-002 in non-muscle invasive bladder cancer (NMIBC). Among BCG-naïve patients, TARA-002 achieved a complete response (CR) at any time in 72.4% of patients (21 out of 29 evaluable cases), with a notable 55% 12-month CR rate (11 out of 20 patients).
| Time Point | CR Rate (%) | Patient Count (CR/Total) |
|---|---|---|
| Any Time | 72.41 | 21/29 |
| 6 Months | 66.67 | 18/27 |
| 12 Months | 55.00 | 11/20 |
Safety Profile Remains Favorable—No Severe Treatment-Related Adverse Events
One striking aspect of TARA-002’s profile is its tolerability. The majority of treatment-related adverse events (TRAEs) observed during the study were mild (Grade 1) and transient. There were no Grade 3 or more severe TRAEs reported, and no patients discontinued treatment due to adverse effects. The most commonly reported TRAEs included dysuria, fatigue, and hematuria, all of which are manageable in the clinical setting.
Competitive Complete Response Durability Compared to Existing and Investigational Options
What makes the ADVANCED-2 data stand out is the sustained response observed over a full year. The 12-month CR rate of 55%, together with Kaplan-Meier estimates suggesting a 73.1% probability of maintaining CR for six months (95% CI: 52.9, 93.4), suggests TARA-002’s durability holds up against approved and experimental therapies for BCG-naïve NMIBC.
Among responders:
- 91.7% (11 of 12) maintained their CR from nine to twelve months.
- 66.7% (4 of 6) of re-induced patients achieved a six-month CR.
Next Steps—Registration Trial Planned for Late 2026
With the BCG-naïve cohort fully enrolled and the data showing both effectiveness and safety, Protara is paving the way for the ADVANCED-3 registrational trial. This next study will compare TARA-002 directly with intravesical chemotherapy in both BCG-naïve and potentially BCG-exposed patients, targeting the second half of 2026 for initiation.
Key Takeaway: TARA-002 Could Transform NMIBC Treatment if Future Data Remain Positive
The strong complete response rates and lack of severe side effects make TARA-002 a therapy to watch as NMIBC patients—especially those for whom current bladder-sparing options are limited—await safer and more effective treatments. Investors and clinicians will want to keep an eye on further data releases as Protara moves toward later-phase trials, with the goal of addressing a significant unmet medical need in bladder cancer care.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI